Focused On-demand Library for Ribosomal protein uL16-like

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Our library is unique due to several crucial aspects:

Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

Q96L21

UPID:

RL10L_HUMAN

Alternative names:

60S ribosomal protein L10-like; Large ribosomal subunit protein uL16-like

Alternative UPACC:

Q96L21; Q8IUD1

Background:

Ribosomal protein uL16-like, also known as 60S ribosomal protein L10-like, plays a pivotal role in protein synthesis within the cell. It is a testis-specific component of the ribosome, essential for the transition from prophase to metaphase in male meiosis I. This protein compensates for the inactivated X-linked RPL10 paralog during spermatogenesis, showcasing a unique ribosomal polypeptide exit tunnel that regulates the biosynthesis and folding of male germ-cell-specific proteins crucial for sperm formation.

Therapeutic significance:

Given its critical role in spermatogenesis, Ribosomal protein uL16-like is directly associated with Spermatogenic failure 63, a disorder marked by severe oligozoospermia and reduced sperm motility. Understanding the role of Ribosomal protein uL16-like could open doors to potential therapeutic strategies for male infertility.